1. Home
  2. AWRE vs AKTX Comparison

AWRE vs AKTX Comparison

Compare AWRE & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aware Inc.

AWRE

Aware Inc.

N/A

Current Price

$2.09

Market Cap

44.5M

Sector

Technology

ML Signal

N/A

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.27

Market Cap

14.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AWRE
AKTX
Founded
1986
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.5M
14.4M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
AWRE
AKTX
Price
$2.09
$0.27
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$3.30
AVG Volume (30 Days)
30.9K
2.6M
Earning Date
10-29-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$17,428,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.72
N/A
52 Week Low
$1.37
$0.22
52 Week High
$2.95
$1.73

Technical Indicators

Market Signals
Indicator
AWRE
AKTX
Relative Strength Index (RSI) 36.04 32.62
Support Level $1.99 $0.24
Resistance Level $2.17 $0.31
Average True Range (ATR) 0.09 0.05
MACD -0.00 0.01
Stochastic Oscillator 9.62 18.56

Price Performance

Historical Comparison
AWRE
AKTX

About AWRE Aware Inc.

Aware Inc is a provider of software and services to the biometrics industry. The company's software products are used in government and commercial biometrics systems to identify or authenticate people. The government applications of biometrics systems include border control, visa applicant screening, law enforcement, national defense, intelligence, secure credentialing, access control, and background checks. Its commercial applications include user authentication for login to mobile devices, computers, networks, and software programs, user authentication for financial transactions and purchases. Its geographical segments include the United States, the United Kingdom, and the Rest of the world, out of which it derives maximum revenue from United States.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: